The Wall Street Journal: Bausch + Lomb prices IPO at $18 a share, below expectations


Bausch + Lomb Corp.

 priced its IPO at $18 a share Thursday, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market.

Bausch Health Cos.
the parent company, raised $630 million in the offering. It had been aiming to raise as much as $840 million and sell the stock at $21 to $24 a share, according to a regulatory filing. The Wall Street Journal had previously reported the deal was likely to price at the low end or below the range.

Read: U.S. IPO market bracing for second biggest deal of the year so far in eye-care health company Bausch + Lomb

The debut of the eye-care company, a spinoff of Bausch Health Cos., is being watched closely as a bellwether for the IPO market, which has been virtually shut down since stocks started falling earlier this year. It is the first big initial public offering since private-equity firm TPG Inc.

 went public in mid-January. After a record year in 2021, traditional IPOs have raised less than $3.3 billion in 2022, the slowest start since 2016, according to Dealogic.

Bausch is a fitting test case for the IPO market, which provides a crucial spigot of cash and visibility to startups and Wall Street alike. The company is profitable and a well-established name in its industry.

An expanded version of this report appears on

Also popular on

Mastering the art of ‘failing up’ at work.

Unexplained attacks inside Russian territory raise prospect of wider conflict.

Earnings Results: DaVita stock falls as higher wages, missed treatments push earnings below Street expectations

Previous article

Key Words: Sen. Elizabeth Warren questions Fidelity’s ‘risky and speculative’ plan to offer bitcoin in 401(k)s

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News